TIBSOVO is the first targeted therapy to show improved event-free survival and overall survival in combination with azacitidine compared to azacitidine monotherapy. Safety profile consistent with previously published data in patients with IDH1-mutated acute myeloid leukemia. The study recently halted further enrollment due to compelling efficacy data for TIBSOVO. Servier, a global pharmaceutical company, today announced the global Phase 3 double blinded placebo controlled AGILE study of TIBSOVO